文献速递肝病

人工智能在NAFLD和NASH诊断与风险分层中的应用:现状综述

Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
PubMed 文献 · Hepatology · 2021-08-10

非酒精性脂肪性肝病(NAFLD)及纤维化的诊断因缺乏症状和可用检测而困难,肝活检是当前标准但难以规模化。本文综述人工智能在NAFLD/NASH诊断与风险分层中的应用现状,指出AI有望在关键诊疗节点辅助管理。

要点

  • NAFLD全球患病约每3至4人中1人,肝活检难以作为常规诊断工具。
  • 缺乏简单可重复的纵向随访方法,使随访和治疗决策复杂化。
  • 人工智能有潜力用于NAFLD/NASH表型的诊断与风险分层。

核心结论

  • 人工智能有望在NAFLD患者诊疗关键节点辅助诊断与风险分层,以应对肝活检不可规模化的困境。

研究设计与样本

  • 综述类文章,基于现有NAFLD知识总结人工智能在诊断与风险分层中的应用。

主要发现

  • NAFLD全球患病约每3至4人中1人,肝活检虽为当前诊断、风险分层和监测标准,但难以在该人群中常规实施。
  • 缺乏简单可重复的纵向随访方法,使NAFLD患者的随访与治疗决策复杂化。

临床怎么用

  • 在NAFLD诊疗中可关注人工智能方法用于诊断和风险分层的应用前景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnosis of nonalcoholic fatty liver disease and associated fibrosis is challenging given the lack of signs, symptoms and nonexistent diagnostic test. Furthermore, follow up and treatment decisions become complicated with a lack of a simple reproducible method to follow these patients longitudinally. Liver biopsy is the current standard to detect, risk stratify and monitor individuals with nonalcoholic fatty liver disease. However, this method is an unrealistic option in a population that affects about one in three to four individuals worldwide. There is an urgency to develop innovative methods to facilitate management at key points in an individual's journey with nonalcoholic fatty liver disease fibrosis. Artificial intelligence is an exciting field that has the potential to achieve this. In this review, we highlight applications of artificial intelligence by leveraging our current knowledge of nonalcoholic fatty liver disease to diagnose and risk stratify NASH phenotypes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Dinani AM, Kowdley KV, Noureddin M, et al. Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. Hepatology. 2021. PMID: 33928671. doi:10.1002/hep.31869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。